BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $24

Futu News30minutes ago · Ratings

Express News | Travere Therapeutics Inc: Expects Fiscal Year 2024 Net Product Sales to Be Approximately $227 Mln

BreakingsJan 13 20:05

Express News | Travere Therapeutics Inc: On Track to Provide Regulatory Update on Sparsentan in Fsgs by Its Q4 2024 Earnings Call

BreakingsJan 13 20:05

Press Release: Travere Therapeutics Provides Corporate Update and 2025 Outlook

Dow JonesJan 13 20:01

Express News | Travere Therapeutics- Snda for Modification of Liver Monitoring for Filspari in Igan Accepted for FDA Review ; Pdufa Target Action Date of Aug 28

BreakingsJan 13 20:00

Express News | Travere Therapeutics Provides Corporate Update and 2025 Outlook

BreakingsJan 13 20:00